Skyhawk Therapeutics

Skyhawk Therapeutics, based in Waltham, Massachusetts, focuses on developing innovative small molecules that modify RNA expression to treat complex diseases, primarily in neurology, oncology, and fibrotic diseases. Skyhawk Therapeutics, founded in 2016 by Bill Haney, is dedicated to modifying RNA expression for therapeutic purposes. The company has successfully completed three funding rounds, with its most recent venture funding of USD 133. 00 mn raised on September 14, 2021, led by Fidelity Management and Research Company, alongside Rock Springs Capital and GreatPoint Ventures.

The company operates from its headquarters in Waltham, Massachusetts, US. Skyhawk Therapeutics specializes in developing novel small molecules that modify RNA expression, targeting complex diseases in neurology, oncology, and fibrotic diseases. Its core products include SKY-0515, an RNA splicing modulator for Huntington's Disease, and SKY-1300 and SKY-1500 for Spinocerebellar Ataxia Type 3 and Frontotemporal Dementia, respectively. The company utilizes its proprietary SKYSTAR® platform and collaborates with major pharmaceutical firms such as BMS, Biogen, and Sanofi to address unmet medical needs globally, including North America, Europe, and Australia.

Skyhawk Therapeutics has established a financial foundation exceeding USD 525 mn through strategic partnerships with leading pharmaceutical companies. Its revenue model is primarily B2B, focusing on collaborations for co-developing RNA-targeting therapeutics, involving upfront payments, milestones based on clinical development, and royalties from product sales. The flagship product SKY-0515 underscores the potential revenue generated from milestones during clinical trials, emphasizing collaboration with partners for therapeutic distribution. Following its recent funding of USD 133.

00 mn on September 14, 2021, Skyhawk Therapeutics plans to accelerate the development of its RNA-modifying drug candidates into clinical trials. The company aims to expand its product pipeline and enter new markets, including additional regions in Europe and Asia by 2023. The funding will be utilized to advance the clinical development processes of its novel therapeutics.